TY - JOUR
AU1 - Bech, Per
AU2 - Tomba, Elena
AB - We are very grateful to Snowden [1] for using our pharmacopsychometric triangle [2] and our clinimetric considerations [3] when investigating the collaborative relationship between the patient and his or her psychiatrist. His figure 1 is based on a placebo-controlled trial in schizophrenic patients [4] which was subsequently clinimetrically analysed [2] in order to validate the scales for antipsychotic effect, for extrapyramidal side effects, and for antidepressive effect in a haloperidol dose-response evaluation by use of effect size statistics.In their review on the psychopharmacology of schizophrenia, Lehmann and Ban [5] showed that very early in the history of haloperidol for acute schizophrenia it was recognized that its pharmacological action was correlated with its effect on the extrapyramidal system; this was observed in doses from 2 to 5 mg daily. Now, 50 years after the introduction of haloperidol for acute schizophrenia Bentall [6] demonstrated that a depressive syndrome is part of the effect of haloperidol on the extrapyramidal system. The pharmacopsychometric triangle (fig. 1 in Snowden's paper) clearly demonstrates that a dose of 16 mg haloperidol daily is associated with extrapyramidal symptoms (an effect size of -0.48) without any antidepressive effect (an effect size close to 0). In a recent trial 
TI - Reply
JF - Psychotherapy and Psychosomatics
DO - 10.1159/000348508
DA - 2013-01-01
UR - https://www.deepdyve.com/lp/karger/reply-hlk58mQSHx
SP - 259
EP - 259
VL - 82
IS - 4
DP - DeepDyve
ER -